Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) --...

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...